• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Interns driven by Truveta’s mission, culture stay on as full-time employees

Interns driven by Truveta’s mission, culture stay on as full-time employees

by Truveta staff | Mar 10, 2022 | Culture

When Anirudh “Ani” Pochiraju, 27, walks into the Truveta office, the “Cheers” theme song comes to mind as his team welcomes him to work. “It’s like everybody knows your name,” he said. “I kind of felt like I’d walk in (and) I just felt like everyone knew me. Everyone...
A first look at Truveta at #ViVE2022  – and taking on the big challenge of building trust in medical insights

A first look at Truveta at #ViVE2022 – and taking on the big challenge of building trust in medical insights

by Terry Myerson, CEO | Mar 8, 2022 | News

Today in a keynote at ViVE, I unveiled the Truveta platform for the first time with its first public demonstration. While preparing for this keynote, I reflected on how far our team, and our members, have come in the last two years, amidst the backdrop of the COVID-19...
COVID-19 breakthrough infection rates by co-morbidity during Omicron wave

COVID-19 breakthrough infection rates by co-morbidity during Omicron wave

by Truveta Research | Mar 8, 2022 | Research, Research Insights

After looking at the Truveta COVID-19 dashboard, our Research Team was curious about the breakthrough rates for specific disease types and how they compared between fully vaccinated individuals with and without booster shots. The team took the data in the dashboard...
Next Entries »

Share this


Recent posts

  • Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers
  • Top 5 takeaways from Truveta Symposium 2025
  • Women’s health: Pain medication remains rare for women receiving IUDs

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Get started

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Interested in learning more?

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice